Novo Nordisk strengthens its technology position in inhalable insulin  

Novo Nordisk has acquired patent rights from US company Aradigm Corporation, which concern the administration of proteins via inhalation

Novo Nordisk has entered an agreement with Aradigm Corporation, which secures the US firm DKK 165 m (USD 27.5 m) in fresh capital. In return Novo Nordisk acquires certain patent rights as part of a restructuring of the existing licence agreement regarding AERx iDMS [insulin Diabetes Management System – Ed], which is Novo Nordisk’s electronic delivery system for administering human insulin by inhalation. AERx iDMS entered phase 3 development in May 2006.

The concept of inhalable insulin is based on the fact that the alveoli in the lungs, which take up oxygen from the atmosphere and excrete carbon dioxide from the body, are very good at absorbing medications with a low molecular weight. The patents which Novo Nordisk has acquired relate to administration of proteins via inhalation, and will further strengthen Novo Nordisk’s position in the area of inhalable insulin. The news was reported by financial daily newspaper Børsen.

Novo Nordisk is headquartered in Bagsværd, north of Copenhagen, and employs 22,000 people in 79 countries. The company has the broadest product portfolio in the diabetes industry, including advanced products in the area of insulin delivery systems. It also has a leading position in areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London.

Link > Novo Nordisk 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×